Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07010497 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

Study acronym: IAPETUS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 1 to 3v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 14, 2025 to Mar 16, 2026
    • Site details revised
    • Eligibility criteria expanded, about 1 word
    v3
  3. Study description expanded, about 4 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Asan Medical Center
92 trials monitored
See 1 trial at risk
Liver Cancer
1,598 trials monitored
See 71 trials at risk
This is a phase 2, open-label study to evaluate the safety, tolerability and efficacy of Irpagratinib in combination with Atezolizumab and Bevacizumab in patients with advanced or unresectable HCC harboring FGF19 overexpression. This study composes two parts, a Safety Run-in part to evaluate safety and establish the dose of Irpagratinib for the triple combination, and an Expansion part to evaluate the preliminary efficacy and safety using Simon's two-stage design.
Trial Details
NCT Number NCT07010497
Lead Sponsor Asan Medical Center
Collaborators: Abbisko Therapeutics Co, Ltd
Conditions
(from sponsor)		 Carcinoma, Hepatocellular
Related terms Carcinoma, Hepatocellular
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov